Alkermes (NASDAQ:ALKS) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Alkermes (NASDAQ:ALKS) released its quarterly earnings data on Wednesday. The company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.81 by $0.11, Zacks reports. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. Alkermes updated its FY 2025 guidance to 1.030-1.210 EPS.

Alkermes Stock Up 4.8 %

Shares of NASDAQ ALKS opened at $33.50 on Thursday. The company has a quick ratio of 3.03, a current ratio of 3.45 and a debt-to-equity ratio of 0.22. The firm has a market cap of $5.42 billion, a PE ratio of 17.18, a P/E/G ratio of 1.83 and a beta of 0.49. The company’s fifty day simple moving average is $30.16 and its 200 day simple moving average is $28.65. Alkermes has a 12-month low of $22.90 and a 12-month high of $33.73.

Insider Activity

In other Alkermes news, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the transaction, the director now owns 23,013 shares in the company, valued at approximately $732,964.05. This represents a 10.47 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Christian Todd Nichols sold 5,208 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a total value of $151,813.20. Following the sale, the senior vice president now owns 60,703 shares of the company’s stock, valued at approximately $1,769,492.45. This represents a 7.90 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 179,189 shares of company stock worth $5,723,518. Company insiders own 4.89% of the company’s stock.

Analyst Ratings Changes

ALKS has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft began coverage on Alkermes in a research note on Tuesday. They issued a “buy” rating and a $40.00 price objective for the company. Mizuho increased their price objective on Alkermes from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. cut their target price on Alkermes from $32.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. The Goldman Sachs Group reduced their target price on Alkermes from $32.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, October 25th. Finally, Piper Sandler restated an “overweight” rating and set a $37.00 price target (down previously from $38.00) on shares of Alkermes in a report on Friday, October 25th. One analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $37.08.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.